Opinion of the Transparency Council – valsartanum + indapamidum
At its meeting on 13 May 2025, the Transparency Council adopted opinion No. 84/2025 on the inclusion of medicinal products containing the active substances valsartanum + indapamidum in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. hypertension